title: Is extended or continuous infusion of carbapenems the obvious solution to improve clinical outcomes and reduce mortality?
authors.forename: Frédéric
authors.initials: F
authors.lastname: Frippiat
authors.forename: Christelle
authors.initials: C
authors.lastname: Vercheval
authors.forename: Bernard
authors.initials: B
authors.lastname: Lambermont
authors.forename: Pierre
authors.initials: P
authors.lastname: Damas
mesh_terms: D000900:Anti-Bacterial Agents / Q000008:administration & dosage*; D001424:Bacterial Infections / Q000188:drug therapy*; D015780:Carbapenems / Q000008:administration & dosage*; D006801:Humans; D010397:Penicillanic Acid / Q000031:analogs & derivatives*; D010878:Piperacillin / Q000008:administration & dosage*
chemical_list: D000900:Anti-Bacterial Agents; D015780:Carbapenems; D010397:Penicillanic Acid; D010878:Piperacillin